Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 100 от 154

Активно (без набиране) Фаза 1

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Cancer-Neoplasms

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab. The study will enroll adult participants with selected locally advanced and/or metastatic solid tumors for whom standard therapy does not exist, or has proven to be ineffective or intolerable.

Начало: 16.09.2024 Край: 10.08.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +2 Hoffmann-La Roche NCT06537310

Активно (без набиране) Фаза 3

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Uveitis, Posterior Uveitis, Intermediate Uveitis

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Начало: 11.09.2024 Край: 01.02.2028 Възраст: 18–75 г. Лечение

Argentina, Australia, Belgium +9 Priovant Therapeutics, Inc. NCT06431373

Активно (без набиране) Фаза 2

A Phase 2b Study of Zagociguat in Patients With MELAS

Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)

PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.

Начало: 10.09.2024 Край: 20.06.2026 Възраст: 18–75 г. Лечение

Australia, Canada, Germany +3 Tisento Therapeutics NCT06402123

Активно (без набиране) Фаза 3

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

Начало: 04.09.2024 Край: 07.05.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Bulgaria +17 Takeda NCT06550076

Активно (без набиране) Фаза 3

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Pulmonary Arterial Hypertension

This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study

Начало: 03.09.2024 Край: 01.12.2026 Възраст: 18–75 г. Лечение

Argentina, Australia, Belgium +25 GB002, Inc. NCT06274801

Активно (без набиране) Фаза 1/2

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

MSI-H/dMMR Gastroesophageal-junction Cancer MSI-H/dMMR Gastric Cancer

This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.

Начало: 31.08.2024 Край: 01.08.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +11 Servier Bio-Innovation LLC NCT06116136

Активно (без набиране) Фаза 3

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.

Начало: 30.08.2024 Край: 30.01.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +28 Alpine Immune Sciences Inc, A Subsidiary of Vertex NCT06564142

Активно (без набиране) Фаза 2

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Lymphoma, Follicular

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

Начало: 30.08.2024 Край: 27.11.2028 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +10 Celgene NCT06425302

Активно (без набиране) Фаза 2

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

Coeliac Disease Celiac Disease

This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE). The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will assess the effect of amlitelimab when compared to placebo on gluten induced changes in the intestinal mucosa as measured by the villous height to crypt depth (Vh:Cd) ratio. The effect of amlitelimab on participant-reported celiac signs and symptoms along with the safety, tolerability, and pharmacokinetics of amlitelimab will also be studied. Study details include: The study duration will be up to 48 weeks (including a 16-week safety follow-up period) with 10 visits for participants who opt not to enter the optional long-term extension. The study duration will be up to 172 weeks (including an 8-week safety follow-up period) with 22 visits for participants who enter the optional long-term extension. The double-blind placebo-controlled treatment duration will be up to 28 weeks.

Начало: 29.08.2024 Край: 10.04.2029 Възраст: 18–75 г. Лечение

Argentina, Australia, Belgium +18 Sanofi NCT06557772

Активно (без набиране) Фаза 1

A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants

COVID-19

A study to investigate the safety, tolerability, and pharmacokinetics of a SARS-CoV-2-directed monoclonal antibody in healthy participants

Начало: 28.08.2024 Край: 01.05.2025 Възраст: 18–65 г. Друго

Australia Invivyd, Inc. NCT06523153

Активно (без набиране) Фаза 2

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

Moderate to Severe Crohn's Disease

This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.

Начало: 28.08.2024 Край: 14.05.2027 Възраст: 18–80 г. Лечение

Argentina, Australia, Belgium +23 AstraZeneca NCT06450197

Активно (без набиране) Фаза 3

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Endometrial Cancer

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).

Начало: 28.08.2024 Край: 01.06.2029 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +16 Gilead Sciences NCT06486441

Активно (без набиране) Фаза 2

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Locally Advanced Breast Cancer Triple Negative Breast Cancer Metastatic Triple Negative Breast Cancers

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).

Начало: 26.08.2024 Край: 01.06.2029 Възраст: от 18 г. Лечение

Australia, Turkey (Türkiye), United Kingdom +1 BioNTech SE NCT06449222

Активно (без набиране) Фаза 2

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancer at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cells after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS). PFS is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.

Начало: 20.08.2024 Край: 02.09.2030 Възраст: 18–70 г. Лечение

Australia, Brazil, Germany +2 Janssen Research & Development, LLC NCT06577025

Активно (без набиране) Фаза 3

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 360 adult participants with R/R DLBCL will be enrolled in approximately 165 sites across the world. Participants in arm A will receive subcutaneous (SC) injections of epcoritamab plus oral lenalidomide capsules (E-Len) for up to 12 cycles (each cycle is 28 days). Participants in arm B will receive intravenously (IV) infused R-GemOx for up to 4 cycles (each cycle is 28 days). Participants in arm C will receive SC injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Начало: 13.08.2024 Край: 01.03.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Genmab NCT06508658

Активно (без набиране)

MagDI Australia Study

Obesity Type 2 Diabetes

The objective of the MagDI Australia Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion (e.g., one example of a small bowel clinical procedure requiring a side-to-side anastomosis).

Начало: 13.08.2024 Край: 20.06.2026 Възраст: 18–65 г. Лечение

Australia GT Metabolic Solutions, Inc. NCT06473831

Активно (без набиране) Фаза 1

A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults

Healthy Volunteers

The main purposes of this study are to assess the safety, reactogenicity and immunogenicity of 4 dose levels of the bivalent combination Respiratory Syncytial Virus (RSV) / human Metapneumovirus (hMPV) vaccine candidate VXB-241 when administered as a single-dose regimen to healthy adults 60 to 83 years of age, and to assess the impact of revaccination approximately 1 year later.

Начало: 13.08.2024 Край: 01.05.2027 Възраст: 18–83 г. Превенция

Australia Vicebio Australia Proprietary Limited NCT06556147

Активно (без набиране) Фаза 1/2

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.

Начало: 07.08.2024 Край: 01.07.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +10 Servier Bio-Innovation LLC NCT06162572

Активно (без набиране) Фаза 1

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Advanced Solid Tumor

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after the treatment period.

Начало: 07.08.2024 Край: 22.02.2027 Възраст: от 18 г. Лечение

Australia, Japan, South Korea +2 EMD Serono Research & Development Institute, Inc. NCT06421935

Активно (без набиране) Фаза 2/3

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

Diabetic Macular Edema (DME)

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.

Начало: 07.08.2024 Край: 31.12.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Colombia +15 EyeBiotech Ltd. NCT06571045

1 … 98 99 100 101 102 … 154